Glucagon-like peptide-1 receptor (GLP-1) agonists, widely used to treat obesity and diabetes, may also improve key outcomes for patients with Crohns disease, according to a large real-world study presented during the 2026 Crohns & Colitis Congress, a partnership of AGA and the Crohn's & Colitis Foundation, taking place in Las Vegas
The global SUSTAIN Phase 3a clinical trial program comprised eight clinical trials (one of which was a 2-year cardiovascular outcomes trial), involving more than 8,000 adults with type 2 diabetes, including adults with high cardiovascular risk profiles, with and without renal disease
Bartholome R, Salden B, Vrolijk MF et al (2015) Paracetamol as a post prandial marker for gastric emptying, a food-drug interaction on absorption
Fat loss stalls
Using IV therapy can drive greater transport of these key mood regulating substances into the brain
Understanding "does insurance cover semaglutide" is crucial for planning your treatment